Drug research

Molgramostim

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Recombinant human GM-CSF; Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF); Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF).

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).NCT06431776	SVRA	Phase 3	Recruiting	2027-06Estimated
Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar ProteinosisNCT03482752	SVRA	Phase 3	Terminated	2021-01-14Actual
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NCT04544293	SVRA	Phase 3	Active not recruiting	2023-11-30Actual

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

SVRARecruitingPrimary completion: 2027-06 · Estimated

Trial details

Registry ID: NCT06431776
Phase: Phase 3

Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

SVRATerminatedPrimary completion: 2021-01-14 · Actual

Trial details

Registry ID: NCT03482752
Phase: Phase 3

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

SVRAActive not recruitingPrimary completion: 2023-11-30 · Actual

Trial details

Registry ID: NCT04544293
Phase: Phase 3

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.